Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients

被引：1
|
作者：
Nakamura, Yukiko [1 ]
Miyazaki, Kazuhito [1 ]
Aiko, Naoto [1 ]
Misumi, Yuki [1 ]
Agemi, Yoko [1 ]
Taniguchi, Yuri [1 ]
Ishi, Mari [1 ]
Shimokawa, Tsuneo [1 ]
Okamoto, Hiroaki [1 ]
Yamanaka, Takeharu [2 ]
机构：
[1] Yokohama Municipal Citizens Hosp, Dept Resp Med, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Sch Med, Dept Biostat, Yokohama, Kanagawa, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 02期
关键词：
Older patients; non-small cell lung cancer; immune checkpoint inhibitor; anti PD-1 inhibitor; overall survival; NIVOLUMAB; DOCETAXEL;
D O I：
10.21873/anticanres.14025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: We assessed the efficacy of immune checkpoint inhibitors (ICIs) in older patients because of the limited information regarding these patients. Patients and Methods: We retrospectively analyzed 66 consecutive patients >= 70 years old with advanced non-small cell lung cancer (NSCLC). A total of 31 patients received ICIs (ICIs group) and 35 patients received only cytotoxic regimens (No ICIs group). Results: Patients with squamous cell carcinoma who received ICIs had better overall survival (OS) than those who did not (9.7 versus 4.7 months, p=0.027). In multivariate analysis, treatment with ICIs [hazard ratio (HR)=0.54, 95% confidence interval (CI)=0.30-0.98, p=0.044], good performance status (HR=0.30, 95%CI=0.16-0.57, p=0.0003), and histology other than squamous cell carcinoma (HR=0.41, 95%CI=0.19-0.83, p=0.014) were significantly favorable factors for OS. Conclusion: ICIs may be effective for older patients with NSCLC, especially squamous cell carcinoma patients.
引用
收藏
页码：923 / 928
页数：6
相关论文
共 50 条
  • [31] The impact of sarcopenia on the efficacy of PD-1 inhibitors in non-small cell lung cancer and potential strategies to overcome resistance
    Liu, Zhenchao
    Lei, Tianxiang
    Guo, Yunliang
    Zheng, Chongwen
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [32] Checkpoint inhibitors in older patients with advanced non-small cell lung cancer
    Reale, Maria Lucia
    Romano, Gianpiero Diego
    Paolelli, Loretta
    Leo, Silvana
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 188
  • [33] The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
    Xie, Mingying
    Li, Na
    Xu, Xiaoling
    Xu, Yanjun
    Li, Hui
    Zhu, Liang
    Sheng, Jiamin
    Zhou, Zichao
    Fan, Yun
    CANCERS, 2022, 14 (17)
  • [34] Comparative efficacy and safety of first-line PD-1/PD-L1 inhibitors in immunotherapy for non-small cell lung cancer: A network meta-analysis
    Liu, Liyan
    Yan, Yilong
    Wang, Yuqiao
    Li, Ziming
    Yang, Li
    Yu, Kefu
    Zhao, Zhigang
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [35] Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD
    Suzuki, Yuzo
    Inui, Naoki
    Karayama, Masato
    Imokawa, Shiro
    Yamada, Takashi
    Yokomura, Koushi
    Asada, Kazuhiro
    Kusagaya, Hideki
    Kaida, Yusuke
    Matsuda, Hiroyuki
    Koshimizu, Naoki
    Toyoshima, Mikio
    Masuda, Masafumi
    Hayakawa, Hiroshi
    Hozumi, Hironao
    Furuhashi, Kazuki
    Enomoto, Noriyuki
    Fujisawa, Tomoyuki
    Nakamura, Yutaro
    Suda, Takafumi
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019, 14 : 1867 - 1877
  • [36] Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection
    Zhao, Zhiting
    Hu, Ran
    Chen, Yan
    Zhou, Guoren
    Yu, Shaorong
    Feng, Jifeng
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) : 366 - 373
  • [37] The impact of body mass index on the efficacy of anti-PD-1/PD-L1 antibodies in patients with non-small cell lung cancer
    Ichihara, Eiki
    Harada, Daijiro
    Inoue, Koji
    Sato, Ken
    Hosokawa, Shinobu
    Kishino, Daizo
    Watanabe, Kazuhiko
    Ochi, Nobuaki
    Oda, Naohiro
    Hara, Naofumi
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    LUNG CANCER, 2020, 139 : 140 - 145
  • [38] Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer
    Zhou, Yuwen
    Xia, Ruolan
    Xiao, Huilang
    Pu, Dan
    Long, Yixiu
    Ding, Zhenyu
    Liu, Jiyan
    Ma, Xuelei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 91
  • [39] Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients
    Koh, Young Wha
    Han, Jae-Ho
    Haam, Seokjin
    Jung, Joonho
    Lee, Hyun Woo
    ONCOIMMUNOLOGY, 2019, 8 (10):
  • [40] Impact of early inflammatory cytokine elevation after commencement of PD-1 inhibitors to predict efficacy in patients with non-small cell lung cancer
    Yuichi Ozawa
    Yusuke Amano
    Kei Kanata
    Hirotsugu Hasegwa
    Takashi Matsui
    Takuya Kakutani
    Takafumi Koyauchi
    Masayuki Tanahashi
    Hiroshi Niwa
    Koshi Yokomura
    Takafumi Suda
    Medical Oncology, 2019, 36
12345